Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the KP.2 ...

Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine ...

PFE along with BioNTech SE BNTX announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...

Pfizer and BioNTech said on Friday that a committee from the European Medicine Agency recommended marketing authorization for its Omicron adapted vaccine to prevent Covid-19, meaning the vaccine is ...

EMA’s human medicines committee recommends marketing approval for Pfizer & BioNTech’s Omicron KP.2-adapted Covid-19 vaccine: New York Monday, September 23, 2024, 10:00 Hrs [IS ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a ...

Pfizer-BioNTech's updated vaccine to protect against a recently circulating variant of COVID-19 is authorized, Health Canada said on Tuesday.

The mRNA vaccine, called Comirnaty, targets the KP.2 subvariant of Omicron, replacing the previous version which targeted the ...

Pfizer Canada says Health Canada has approved its updated COVID-19 vaccine that protects against one of the most recently ...

BioNTech's updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine formulations that protect against ...